Pharmaceutical Benefit–Risk Communication Tools: A Review of the Literature

Abstract : This paper reviews the main tools used by pharmaceutical regulators for communicating benefit-risk medicines information to patients. Two highly successful tools from the environmental/technological and food safety fields - that could be usefully adapted to the pharmaceutical context - are also reviewed. The evolution of benefit-risk medicines communication is first contextualised within the broader risk communication literature. Three distinct goals are then made explicit before critically examining the evidence for and against tools developed in the US (e.g. at the Food and Drug Administration [FDA]) and Europe (e.g. at the European Medicines Agency [EMA]). These are sharing information (e.g. publishing clinical trial and adverse event data online), changing patients' beliefs (e.g. patient information leaflets and the drugs facts box), and changing behaviour (e.g. risk minimisation activities and warning labels). The two tools developed in other risk communication fields - the mental models approach and traffic light labelling - are then examined. Ultimately the paper provides a helicopter view and examination of the variety of benefit-risk communication tools that are used or could be used by pharmaceutical regulators in the US and Europe.
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal-mines-paristech.archives-ouvertes.fr/hal-01421940
Contributeur : Hortense Blazsin <>
Soumis le : vendredi 23 décembre 2016 - 12:00:06
Dernière modification le : lundi 12 novembre 2018 - 11:03:45

Identifiants

Citation

Dominic Way, Hortense Blazsin, Ragnar Löfstedt, Frederic Bouder. Pharmaceutical Benefit–Risk Communication Tools: A Review of the Literature. Drug Safety, Springer Verlag, 2016, ⟨10.1007/s40264-016-0466-1⟩. ⟨hal-01421940⟩

Partager

Métriques

Consultations de la notice

242